<qa>  What is the overall response rate of Acute Myelogenous Luekemia?Prospective, nonrandomized, noncomparative, open-label, multicenter, 2-stage clinical study designed to determine the overall response combined complete remission, complete remission with incomplete blood count recovery, partial remission, or blast response rate following tandutinib therapy in 2 groups of patients with newly diagnosed Acute Myelogenous Luekemia. 